Business
Positive response in COVIDITY trial
Positive response in COVIDITY trial.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n 13 February 2023\n \n \n \n \n \n \n Scancell Holdings plc\n \n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n \n Scancell announces positive response in COVIDITY trial\n \n \n \n \n \n \n \n \n \n COVIDITY vaccine candidates induce neutralising antibody and T cell responses in naïve participants and boost responses in previously vaccinated / infected participants\n \n \n \n \n \n \n \n \n \n The trial validates that AvidiMab®-modified immunotherapies boost immune responses and PharmaJet's needle-free injection device is effective in delivering ImmunoBody\n \n \n ®\n \n \n -generated drug candidates\n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces preliminary immunogenicity data from its Phase 1 COVIDITY clinical trial which was conducted at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the trial were to assess the safety and immunogenicity of two vaccine candidates, SCOV1 and SCOV2, in healthy, vaccine-naïve subjects, prior to testing the candidates as a booster in SARS-CoV-2 pre-infected or pre-vaccinated volunteers. SCOV1 and SCOV2 are both plasmid DNA vaccines based on the Company's ImmunoBody® technology and incorporate its AvidiMab® modifications to further enhance the immune responses induced following vaccination.\n \n \n \n \n \n The data from the Phase 1 COVIDITY trial showed that neutralising antibodies were induced as well as T cell responses to both the receptor binding domain (RBD) of the spike protein and the nucleocapsid antigen (NCAP). In vaccine-naïve subjects, the seroconversion rate (the level of detectable antibodies in the blood due to vaccination) was 67% following SCOV1/SCOV2 vaccination, with a broad reactivity against multiple COVID-19 variants, including the currently dominant Omicron variant. These positive results demonstrate that SCOV1 and SCOV2, delivered via PharmaJet's needle-free injection device, induce immune responses in naïve participants. Additionally, a single dose of SCOV2 boosted broad responses in previously exposed subjects.\n \n \n \n \n \n As previously disclosed, the Board of Scancell have decided not to take this vaccine forward in house due to the larg...